HU · HAN'S UNITED · CLINICAL ARCHIVEFOUNDED 2007 · SHANGRAO
Dossier №
002
/ 010
─── Neurology
Stem cells for autism in China: what is known
Abstract
Stem cells for autism in China: research findings, limitations and questions before travelling to Shangrao. What to discuss with a clinician and which records to prepare.
Cell-based interventions for ASD remain investigational. Speech development, behavioural change or an autism ‘cure’ cannot be promised. A travel decision needs to account for uncertain benefits and risks of the specific intervention.
Autism support is tailored to the child’s communication, daily participation, sleep, learning and coexisting conditions. NICE recommends adapted social-communication interventions involving parents or teachers. This guidance describes ASD support, not the Han’s United programme; a cell intervention should not replace the care the child needs.
Trials examine different products, including cord blood and mesenchymal stromal cells from cord tissue. These are not interchangeable. A large placebo-controlled cord-blood trial did not establish an overall social-communication benefit. A small uncontrolled MSC study primarily examined tolerability. These findings cannot be transferred to every product, administration route or centre’s programme.
A small 2026 placebo-controlled trial of cord-blood mononuclear cells in children with ASD and immune dysregulation reported a positive SRS-2 signal. Its selected population, different cell product and short follow-up matter. This supports further research, not a promise of benefit for every autistic child.
These data cannot predict an individual child’s chance of benefit, a ‘best age’, number of procedures or time to speech development. A score change after a course does not by itself prove a cell effect: development, ongoing support and assessment methods also matter. A family’s account or video describes experience but cannot replace a controlled comparison.
Request the exact product and source, the basis for its use in ASD, quality documentation and specific risks. A trial should provide its registration, ethics approval and follow-up arrangements. Registration alone does not prove efficacy. Discuss the documents with an independent clinician before paying or travelling.
For a case discussion, gather existing specialist reports, developmental and skill-loss history, current support, medicines, allergies and seizure history. Include available investigations and developmental assessments. This is preparation for discussion, not a request to arrange MRI, EEG or laboratory tests yourself; a clinician determines whether new tests are needed. Links below provide the Shangrao contact details and enquiry process.
Costs and length of stay
This page does not quote a fixed price for an ‘autism course’. Before a travel decision, obtain an itemised written estimate for medical services, investigations, accommodation, interpretation and assistance. Clarify inclusions and who pays for complication care and follow-up after returning home. The site price page provides general information; applicability to the individual child needs separate confirmation.
Clinical evidence
Studies and clinical guidance
The study designs and limits of their findings are described below. A publication about a cell product does not automatically establish the efficacy of a particular centre’s programme.
Landmark study01
The Journal of Pediatrics·2020
Dawson G, Sun JM, Baker J, et al.
Dawson G, Sun JM, Baker J, et al. A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. J Pediatr. 2020;222:164-173.e5.
Double-blind RCT, 180 children: cord blood did not improve the primary social-communication outcome in the overall sample at 6 months. Subgroup signals need confirmation. The study tested cord blood, not MSCs or exosomes.
Zhang Z, Wang G, Han F, et al. UCB-MNCs in children with ASD and immune dysregulation: randomized placebo-controlled trial. Stem Cell Res Ther. 2026;17:301.
Single-centre double-blind RCT: 34 children analysed, limited to ASD with immune dysregulation. The authors reported SRS-2 improvement after UCB-MNCs at 13 weeks. The small selected sample and short follow-up prevent generalisation to all children, MSCs or exosomes.
Sun JM, Dawson G, Kurtzberg J, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med. 2020;9(10):1137-1146.
Open-label phase I, 12 children, no control group. It assessed IV hCT-MSC tolerability; five participants developed new anti-HLA antibodies. Observed behavioural changes do not establish efficacy or rule out rare risks.
NICE. Autism spectrum disorder in under 19s: support and management. Clinical guideline CG170.
Guidance on individual support, communication and coexisting conditions in ASD. It covers care for children and young people, not evidence of cell-intervention efficacy.
This overview of published evidence is for discussion with a clinician. It is not an individual prescription or confirmation of eligibility for a cell intervention.
